What were Aptus Pharma Ltd's latest quarterly results?
Aptus Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +60.3% (insufficient data)
- Revenue Growth YoY: +117.6%
- Operating Margin: 14.0% (volatile)
Aptus Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +49.8%WeakNew This Week
In , Aptus Pharma Ltd (Trading) is outperforming Nifty 500 with +49.8% relative strength. Fundamentals: Weak.
Aptus Pharma Ltd Key Facts
- PE Ratio
- 131.0x
- Market Cap
- ₹607 Cr
- PAT Growth YoY
- +60%
- Revenue Growth YoY
- +118%
- OPM
- 14.0%
- RS vs Nifty 500
- +49.8%
Avoid
What's Happening
🚫No earnings growth, no valuation discount — limited upside
💪Debt reduced 31% YoY — balance sheet strengthening
🌐FII stake increased 10.0% this quarter
🏛️DII accumulation — stake up 2.8%
Key Numbers
PAT Growth YoY
+60%
Insufficient Data
Revenue YoY
+118%
Insufficient Data
Operating Margin
14.0%
-541 bps YoY
PE Ratio
131.0
Current Price
₹354
Fundamental Score
37/100
Weak
3Y PAT CAGR
+80%
Market Cap
595 Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Aptus Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +118% | +50% | Insufficient Data |
| PAT (Net Profit) | +60% | +80% | Insufficient Data |
| OPM | 14.0% | -541 bps | Volatile |
Other Top Trading Stocks Beating Nifty 500
Frequently Asked Questions: Aptus Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Aptus Pharma Ltd's profit growing or declining?
Aptus Pharma Ltd's profit is growing with an insufficient data trend.
- PAT Growth YoY: +60.3% (latest quarter)
- PAT Growth QoQ: +64.0% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Insufficient data — consistent growth pattern
What is Aptus Pharma Ltd's revenue growth trend?
Aptus Pharma Ltd's revenue growth trend is insufficient data.
- Revenue Growth YoY: +117.6%
- Revenue Growth QoQ: +123.9% (sequential)
- 3-Year Revenue CAGR: +49.6%
How is Aptus Pharma Ltd's operating margin trending?
Aptus Pharma Ltd's operating margin is volatile.
- Current OPM: 14.0%
- OPM Change YoY: -5.4% basis points
- OPM Change QoQ: -6.4% basis points
What is Aptus Pharma Ltd's 3-year profit and revenue CAGR?
Aptus Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +49.6%
Is Aptus Pharma Ltd's growth accelerating or decelerating?
Aptus Pharma Ltd's earnings growth is insufficient data with mixed signals on a sequential basis.
- YoY Acceleration: +26.7% bps
- Sequential Acceleration: +52.2% bps
- Margin Warning: Operating margins are under pressure
What is Aptus Pharma Ltd's current PE ratio?
Aptus Pharma Ltd's current PE ratio is 131.0x.
- Current PE: 131.0x
- Market Cap: 607 Cr
What is Aptus Pharma Ltd's price-to-book ratio?
Aptus Pharma Ltd's price-to-book ratio is 26.0x.
- Price-to-Book (P/B): 26.0x
- Book Value per Share: ₹14
- Current Price: ₹354
Is Aptus Pharma Ltd a fundamentally strong company?
Aptus Pharma Ltd is rated Weak with a fundamental score of 37/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +117.6% (10% weight)
- PAT Growth YoY: +60.3% (10% weight)
- PAT Growth QoQ: +64.0% (10% weight)
- Margins stable (10% weight)
Is Aptus Pharma Ltd debt free?
Aptus Pharma Ltd's debt position
- Total Debt: ₹7 Cr
What is Aptus Pharma Ltd's return on equity (ROE) and ROCE?
Aptus Pharma Ltd's return ratios over recent years
- FY2024: ROCE 26.5%
- FY2025: ROCE 38.2%
- FY2026: ROCE 30.0%
Is Aptus Pharma Ltd's cash flow positive?
Aptus Pharma Ltd's operating cash flow is negative (FY2026).
- Cash from Operations (CFO): ₹-6 Cr
- Free Cash Flow (FCF): ₹-12 Cr
- CFO/PAT Ratio: -121% (weak cash conversion)
What is Aptus Pharma Ltd's dividend yield?
Aptus Pharma Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹354
Who holds Aptus Pharma Ltd shares — promoters, FII, DII?
Aptus Pharma Ltd's shareholding pattern (Jun 2026)
- Promoters: 72.9%
- FII (Foreign): 0.0%
- DII (Domestic): 0.0%
- Public: 27.1%
Is promoter holding increasing or decreasing in Aptus Pharma Ltd?
Aptus Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 72.9% (Jun 2026)
- Previous Quarter: 72.9% (Mar 2026)
- Change: 0.00% (stable)
How long has Aptus Pharma Ltd been outperforming Nifty 500?
Aptus Pharma Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Aptus Pharma Ltd a new momentum entry or an established outperformer?
Aptus Pharma Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Aptus Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Aptus Pharma Ltd may be worth studying
- Earnings growing at +60.3% YoY
What is the investment thesis for Aptus Pharma Ltd?
Aptus Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +117.6% YoY
Risk Factors (Bear Case)
- Margins under pressure
What is the future outlook for Aptus Pharma Ltd?
Aptus Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: insufficient data
- Revenue Trend: insufficient data
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.